EMA To Share Generics Data To Speed Access, But Pitfalls Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has announced that it is ready to share information on generic marketing authorizations with other regulators, which should speed market access, but industry remains concerned about patent linkage and discriminatory regulatory standards.
You may also be interested in...
EU/U.S. Trade Pact Talks May Stumble Over Drug Regulation, Affordability
The EU Parliament’s health committee has highlighted regulatory pitfalls within TTIP, while civil society elements decry its lack of transparency and potential impact on health care affordability.
European Commission May Pursue More Antitrust Actions Against Pharma
The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.